<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127267</url>
  </required_header>
  <id_info>
    <org_study_id>AB19001</org_study_id>
    <nct_id>NCT03127267</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients</brief_title>
  <official_title>A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to compare the efficacy and safety of masitinib in combination with riluzole
      versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral
      Sclerosis (ALS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Masitinib is a selective, oral tyrosine kinase inhibitor with neuroprotective capability
      demonstrated via numerous preclinical studies. Two of masitinib's main cellular targets are
      the mast cell and microglia cell. It is well-established that mast cells play a prominent
      role in neuroinflammatory processes. Microglia, resident immune cells of the central nervous
      system (CNS), also constitute an important source of neuroinflammatory mediators and may have
      fundamental roles in numerous neurodegenerative disorders. The development of masitinib in
      ALS is therefore based on the pharmacological action of masitinib in microglia cells and mast
      cells, thereby slowing microglial-related disease progression, reducing neuro-inflammation,
      and modulating the neuronal microenvironment in both central and peripheral nervous systems.
      This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group (two
      ascending dose titrations of masitinib and matching placebo), comparative study of oral
      masitinib in the treatment of patients with amyotrophic lateral sclerosis (ALS).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALSFRS-R</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-Revised.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALSAQ-40</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in ALS quality of life patient questionnaire (ALSAQ-40)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From day of randomization to disease progression or death, assessed for a maximum of 36 months</time_frame>
    <description>Progression free survival (PFS) is defined as the time from randomization to progression (decline of more than 9 points in ALSFRS-R score from baseline) or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in Forced Vital Capacity (FVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HHD</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in evaluation of upper- and lower-limb muscle strength using hand-held dynamometry (HHD)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">495</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Masitinib (4.5) &amp; Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Masitinib (6.0) &amp; Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; Riluzole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive a matched dose placebo, given orally twice daily, in combination with riluzole at 50 mg b.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib (6.0)</intervention_name>
    <description>Masitinib (titration to 6.0 mg/kg/day)</description>
    <arm_group_label>Masitinib (6.0) &amp; Riluzole</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <description>Riluzole 50 mg tablet, treatment per os</description>
    <arm_group_label>Masitinib (4.5) &amp; Riluzole</arm_group_label>
    <arm_group_label>Masitinib (6.0) &amp; Riluzole</arm_group_label>
    <arm_group_label>Placebo &amp; Riluzole</arm_group_label>
    <other_name>Rilutek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>treatment per os</description>
    <arm_group_label>Placebo &amp; Riluzole</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib (4.5)</intervention_name>
    <description>Masitinib (titration to 4.5 mg/kg/day)</description>
    <arm_group_label>Masitinib (4.5) &amp; Riluzole</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria include:

          -  Patients diagnosed with laboratory supported probable, clinically probable or definite
             ALS according to the World Federation of Neurology Revised El Escorial criteria

          -  Patient with a familial or sporadic ALS

          -  ALS disease duration from diagnosis no longer than 24 months at the screening visit

          -  Patient treated with a stable dose of riluzole (100 mg/day) for at least 12 weeks days
             prior to the baseline visit

          -  Patient with an ALSFRS-R score progression between onset of the disease and screening
             of &gt; 0.3 per month, confirmed with an ALSFRS-R score progression of â‰¥ 1 point during a
             12-week run-in period between screening and randomization.

          -  Patient with a score, at screening, of at least 26 overall, including a score of at
             least 3 on item #3 and at least 2 on each of the 12 ALSFRS-R individual component
             items and with a score, at randomization, of at least 2 on each of the 12 ALSFRS-R
             individual component items

        Main exclusion criteria include:

          -  Patient with dementia or significant neurological, psychiatric, systemic or organic
             disease, uncontrolled or that may interfere with the conduct of the trial or its
             results

          -  Patient with a FVC &lt; 60% predicted normal value for gender, height, and age at
             screening and baseline

          -  Pregnant, or nursing female patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Ludolph, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University of Ulm, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Study Coordinator</last_name>
    <phone>+33(0)147200014</phone>
    <email>clinical@ab-science.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology ,University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>Tyrosine kinase inhibitor</keyword>
  <keyword>Lou Gehrig's disease</keyword>
  <keyword>Charcot's disease</keyword>
  <keyword>Motor Neuron disease</keyword>
  <keyword>MND</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

